We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01183416
Recruitment Status : Active, not recruiting
First Posted : August 17, 2010
Last Update Posted : September 6, 2017
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : August 2018
  Estimated Study Completion Date : August 2018